Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Adaphostin
AOB6827
CAS: 241127-58-2
Chemical Name: NSC-680410; 1-Adamantyl 4-((2,5-dihydroxybenzyl)amino)benzoate
1000 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity (mg or Unit) | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|
| 5 | $9.35 | Total: $46.75 |
| 10 | $7.92 | Total: $79.20 |
| 25 | $6.71 | Total: $167.75 |
| 50 | $5.72 | Total: $286.00 |
| 100 | $4.95 | Total: $495.00 |
Overview
Novel VISTA (V-domain immunoglobulin suppressor of T-cell activation) agonist
Novel activator of Fas-mediated death pathway in Bcr/Abl-positive leukaemia
Chemical Properties
| Molecular Formula | C24H27NO4 |
| Molecular Weight | 393.48 |
| CAS Numbers | 241127-58-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | 4-[[(2,5-Dihydroxyphenyl)methyl]amino]benzoic acid tricyclo[3.3.1.13,7]dec-1-yl ester |
| InChl Key | YJZSUCFGHXQWDM-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C24H27NO4/c26-21-5-6-22(27)19(10-21)14-25-20-3-1-18(2-4-20)23(28)29-24-11-15-7-16(12-24)9-17(8-15)13-24/h1-6,10,15-17,25-27H,7-9,11-14H2 |
| SMILES Code | O=C(C4=CC=C(NCC5=C(O)C=CC(O)=C5)C=C4)OC12CC(C3)CC(CC3C2)C1 |
Storage and Handling
0°C (short term), -20°C (long term), desiccated
References
1) Svingen et al (2000) Effects of the bcl/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin.Cancer Res. 6 237 PMID: 10656455
2) Avramis et al (2002) In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother.Pharmacol. 50 479 PMID: 12451475
3) Mow et al (2002) Effects of bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99 664 PMID: 11781252